GLPwatch
Papers (10404)
Page 84 of 174, ranked by citation count.
- New Glucose-Lowering Agents for Diabetic Kidney Disease.
- Applications of peptide hormone ligands for the treatment of dumping and short bowel syndrome.
- Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: <i>post-hoc</i> analysis of the SURMOUNT-5 trial.
- Study protocol of the randomised placebo-controlled GLOBE trial: <i>GL</i>P-1 f<i>o</i>r <i>b</i>ridging of hyperglyca<i>e</i>mia during cardiac surgery.
- Liraglutide reduces hyperglycemia-induced cardiomyocyte death through activating glucagon-like peptide 1 receptor and targeting AMPK pathway.
- Focus on Semaglutide 2.4 mg/week for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis.
- Obesity in 2015: Advances in managing obesity.
- GLP1-RA Add-on Therapy in Patients with Type 2 Diabetes Currently on a Bolus Containing Insulin Regimen.
- Therapeutic efficacy of arginine-rich exenatide on diabetic neuropathy in rats.
- Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide versus DPP-4is in a US real-world setting.
- Euglycemic diabetic ketoacidosis after the initiation of dulaglutide in patient with type 2 diabetes.
- Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway.
- Tirzepatide-Induced Injection Site Reaction.
- Liraglutide treatment in a patient with HIV, type 2 diabetes and sleep apnoea-hypopnoea syndrome.
- Comparative Efficacy of Tirzepatide, Liraglutide, and Semaglutide in Reduction of Risk of Major Adverse Cardiovascular Events in Patients with Obstructive Sleep Apnea and Type 2 Diabetes: Real-World Evidence.
- Efficacy and safety of subgroup analysis stratified by baseline HbA1c in a Japanese phase 3 study of dulaglutide 0.75 mg compared with insulin glargine in patients with type 2 diabetes.
- Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge.
- Semaglutide promotes the proliferation and osteogenic differentiation of bone-derived mesenchymal stem cells through activation of the Wnt/LRP5/β-catenin signaling pathway.
- Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes.
- Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes.
- Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1.
- Effects of glucagon-like peptide-1 receptor stimulation and blockade on food consumption and body weight in rats treated with a cannabinoid CB1 receptor agonist WIN 55,212-2.
- The investigation of therapeutic potential of oxytocin and liraglutide on vincristine-induced neuropathy in rats.
- A Review of the Safety and Adverse Event Profile of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide.
- Semaglutide: a promising new glucagon-like peptide-1 receptor agonist.
- Exploring Predictors of Treatment Response to GLP-1 Receptor Agonists for Smoking Cessation.
- Pharmacokinetics, Pharmacodynamics, and Safety of Dulaglutide After Single or Multiple Doses in Chinese Healthy Subjects and Patients with T2DM: A Randomized, Placebo-Controlled, Phase I Study.
- Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial.
- Exendin-4 attenuates lipopolysaccharides induced inflammatory response but does not protects H9c2 cells from apoptosis.
- Effect of semaglutide on fatty liver disease biomarkers in patients with diabetes and obesity.
- PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.
- Separation of mono- and di-PEGylate of exenatide and resolution of positional isomers of mono-PEGylates by preparative ion exchange chromatography.
- GLP-1 Agonists in Plastic Surgery: Impact on Aesthetic Outcomes-Two Case Reports.
- Short-term impact of tirzepatide on metabolic hypogonadism and body composition in patients with obesity: a controlled pilot study.
- Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment.
- Impact of a dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist tirzepatide on heart rate among patients with type 2 diabetes: A systematic review and pairwise and network meta-analysis.
- Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients.
- Comparison of the effects of Liraglutide, Tirzepatide, and Retatrutide on diabetic kidney disease in db/db mice.
- Oral GLP1 Analog: Where Does the Tide Go?
- Incretin Hormones GLP-1 and GIP Normalize Energy Utilization and Reduce Inflammation in the Brain in Alzheimer's Disease and Parkinson's Disease: From Repurposed GLP-1 Receptor Agonists to Novel Dual GLP-1/GIP Receptor Agonists as Potential Disease-Modifying Therapies.
- National trends in prescription drug expenditures and projections for 2025.
- Liraglutide suppresses obesity and promotes browning of white fat via miR-27b <i>in vivo</i> and <i>in vitro</i>.
- PIONEER REAL UK: A Multi-Centre, Prospective, Real-World Study of Once-Daily Oral Semaglutide Use in Adults with Type 2 Diabetes.
- Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed?
- Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats.
- Exenatide-Modified Deferoxamine-Based Nanoparticles Ameliorates Neurological Deficits in Parkinson's Disease Mice.
- Radiographic Midfacial Volume Changes in Patients on GLP-1 Agonists.
- The effects of anti-obesity medications on bone metabolism: A critical appraisal.
- Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.
- Improvement of Left Ventricular Global Longitudinal Strain after 6-Month Therapy with GLP-1RAs Semaglutide and Dulaglutide in Type 2 Diabetes Mellitus: A Pilot Study.
- Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics.
- Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists.
- Effect of the combination of metformin and fenofibrate on glucose homeostasis in diabetic Goto-Kakizaki rats.
- Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide.
- Impact of Digital Engagement on Weight Loss Outcomes in Obesity Management Among Individuals Using GLP-1 and Dual GLP-1/GIP Receptor Agonist Therapy: Retrospective Cohort Service Evaluation Study.
- Characterization of a site-specific PEGylated analog of exendin-4 and determination of the PEGylation site.
- Effects of the DPP-4 inhibitor, linagliptin, in diet-induced obese rats: a comparison in naive and exenatide-treated animals.
- Self-inducible secretion of glucagon-like peptide-1 (GLP-1) that allows MIN6 cells to maintain insulin secretion and insure cell survival.
- Liraglutide promotes apoptosis of HepG2 cells by activating JNK signaling pathway.